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Multifaceted studies of the DNA interactions and in vitro 
cytotoxicity of anticancer polyaromatic platinum(II) complexes 
Benjamin J. Pages,[a] Jennette Sakoff,[b] Jayne Gilbert,[b] Alison Rodger,[c] Nikola P. Chmel,[c] Nykola C. 
Jones,[d] Sharon M. Kelly,[e] Dale L. Ang,[a] Janice R. Aldrich-Wright.*[a] 
 
Abstract: This paper reports a detailed biophysical analysis of the 
DNA binding and cytotoxicity of six platinum complexes (PCs). They 
are of the type [Pt(PL)(SS-dach)]Cl2, where PL is a polyaromatic 
ligand and SS-dach is 1S,2S-diaminocyclohexane. The DNA binding 
of these complexes was investigated using six techniques including 
ultraviolet and fluorescence spectroscopy, linear dichroism, 
synchrotron radiation circular dichroism, isothermal titration 
calorimetry and mass spectrometry. This portfolio of techniques has 
not been extensively used to study the interactions of such 
complexes previously; each assay provided unique insight. The in 
vitro cytotoxicity of these compounds was studied in ten cell lines 
and compared to the effects of their R,R enantiomers; activity was 
very high in Du145 and SJ-G2 cells, with some sub-micromolar IC50 
values. In terms of both DNA affinity and cytotoxicity, complexes of 
5,6-dimethyl-1,10-phenanthroline and 2,2ʹ-bipyridine exhibited the 
greatest and least activity, respectively, suggesting that there is 
some correlation between DNA binding and cytotoxicity. 
Introduction 
A long-standing aspiration of medicinal inorganic chemists has 
been the development of chemotherapeutic agents that can 
effectively combat cancerous cells, yet overcome the resistance 
and toxicity that plague current clinically used platinum agents.[1] 
Platinum complexes (PCs) with mechanisms of action quite 
different from current agents have been explored as alternatives, 
and have demonstrated in vitro cytotoxicity up to 100 times 
greater than cisplatin in several cell lines.[2] In particular, our 
group has focused on the development of PCs that consist of a 
polyaromatic ligand (PL) and a cyclic amine ancillary ligand (AL) 
in the form [Pt(PL)(AL)]2+.[3] These complexes interact non-
covalently with DNA, often via intercalation, rather than by 
forming permanent adducts. They also induce cell death by a 
different mechanism than cisplatin,[2a, 4] and are potently 
cytotoxic against a variety of cell lines, including some that are 
cisplatin-resistant.[5] Our previous studies have been 
inconclusive as to whether there is a correlation between DNA 
affinity and cytotoxicity; however, these studies have often used 
only one or two spectroscopic techniques to study PC-DNA 
interactions.[6] Moreover, DNA binding affinity is known to vary 
depending on the method of measurement and the conditions 
used, and so separately conducted studies can often provide 
inconsistent results.[7] In this study, we have utilised several 
biophysical assays to study the interactions of six PCs with DNA 
(Figure 1). 
 
Figure 1. The structures of complexes 1–6 and 1ʹ–6ʹ; each AL is highlighted in 
green and each PL in blue. Chloride counter ions have been omitted for clarity. 
* indicates a stereocentre, either S or R. 
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The experimental conditions were kept consistent, where 
possible, for each assay to facilitate comparison of the binding 
data elucidated from the individual techniques. This allowed for 
definitive trends in DNA binding affinity to be determined for the 
six PCs. The complexes studied here incorporated 1S,2S-
diaminocyclohexane (SS-dach) as an AL and one of dipyrido[3,2-
d:2ʹ,3ʹ-f]quinoxaline (dpq), 2,3-dimethyl-dpq (23Me2dpq), 1,10-
phenanthroline (phen), 5,6-dimethyl-phen (56Me2phen), 2,2ʹ-
bipyridine (bpy) and 4,4ʹ-dimethyl-bpy (44Me2bpy) as an PL. The 
use of a variety of PLs allowed for a comparison between the 
DNA affinity and aromatic surface area of these complexes; it is 
known that structural variations can result in different DNA 
binding behaviour for metal complexes.[8] Methylated variants of 
each PL were included due to the proven cytotoxic and DNA 
binding influences of methyl substituents in our complexes,[3, 5b] 
and SS-dach was chosen as the AL as complexes of this ligand 
are the most active overall.[5b] The interactions of complexes 1–6 
with calf-thymus DNA (CT-DNA) and some oligonucleotides 
were analysed using several methods. Firstly, linear dichroism 
(LD), ultraviolet spectroscopy (UV) and isothermal titration 
calorimetry (ITC) were utilised in tandem to gain an overall 
picture of DNA binding mode and affinity. Secondly, fluorescent 
intercalator displacement assays (FIDs) and synchrotron 
radiation circular dichroism (SRCD) experiments were 
undertaken to determine the effect of DNA affinity on the ability 
of each complex to displace competitive binders and stabilise 
the DNA strand, respectively. Thirdly, electrospray ionisation 
mass spectrometry (ESIMS) was used to determine if 1–6 
preferentially bind to any base-pairs. Finally, the cytotoxicity of 
these compounds was determined in ten human cell lines. The 
activity of 1–6 was compared to their enantiomers 1ʹ–6ʹ and to 
the DNA binding results to determine any correlations between 
chemical structure, DNA affinity and cytotoxicity. 
Results and Discussion 
Linear dichroism 
 
The LD spectrum of CT-DNA is characterised by a large 
negative band at ~260 nm. Upon the addition of each PC in this 
study, the band at 260 nm increased in intensity, which suggests 
a lengthening or stiffening of the DNA strand. Additionally, 
negative LD signals appeared at the absorbance wavelengths of 
each PC, which suggests that their aromatic components have 
aligned perpendicular to the DNA strand. The PC signals were 
flattened, broadened and red-shifted relative to their absorbance 
bands (Figure 2). These phenomena together indicate that each 
PC is binding via intercalation to DNA. While the alignment of 
complex 6 is obvious from the LD signal at 321 nm, this complex 
also absorbs at 243 and 206 nm; the same region as CT-DNA. 
The increase of the 260 nm LD peak upon addition of 6 could 
therefore be due to PC alignment only and not a result of DNA 
lengthening. To elucidate the cause of the signal change, the UV 
spectra of 6 and CT-DNA were compared to the induced LD 
signal of DNA+6 (Figure 3). In the induced LD spectrum, the 
peak at 247 nm has a higher relative intensity than the other  
 
Figure 2. LD spectra of CT-DNA (150 μM) with increasing concentration of 
complex 6 (selected concentrations from 40 – 200 μM). Inset: The UV 
spectrum of 6. See Figure S1.6 for spectra of the full concentration range. 
 
Figure 3. Top: The UV spectrum of CT-DNA (red line, 35μM) and complex 6 
(blue line, 21μM), showing ratios to the peak at 243 nm for the former. Bottom: 
The inverted induced LD spectra of CT-DNA (150 μM) bound with 44MEBSS 
(selected concentrations from 50–200 μM), showing ratios to the peak at 247 
nm. 
 







Figure 4. Plots of PC concentration against LD response of CT-DNA (150 μM) 
bound with increasing concentrations of complex 3 at 278 nm (4–488 μM, top) 
and 2 at 260 nm (5–205 μM, bottom). 
two; this indicates that both the alignment of 6 and the 
lengthening of the DNA strand are both occurring, confirming 
that intercalation is the binding mode. Similar absorbance 
contributions were observed for each of complexes 1–5 as they 
all absorb in the same region as CT-DNA. For all PCs studied, 
there are two regions of the titration curve at which the signal in 
the CT-DNA region did not consistently increase with increasing 
PC concentration, despite the spectral evidence for DNA 
lengthening and/or stiffening. The first of these was a decrease 
or only very small increase of DNA signal intensity at 260 nm for 
PC concentrations between 5 and 30 μM. This may be indicative 
of a partial intercalation mode that hinges the DNA and bends it 
rather than full intercalation. The second point at which the LD 
signal did not increase was at high PC concentrations (85–100 
μM); at this point a plateau was reached for complexes 1, 3, 5 
and 6 before the signal began to decrease at ~250 μM (Figure 
4). This suggests that the DNA reached saturation by 
intercalation before another binding mode occurred, which then 
caused the strand to lose its aspect ratio. An electrostatic groove 
binding mode of some kind is likely as the second one. The 
plateau allowed for a binding constant to be determined for the 
first or putative intercalative binding. For complexes 2 and 4, the 
signal loss began to occur before any plateau was reached (at 
approx. 80 and 100 μM, respectively), implying that the second 
binding mode occurred earlier for these complexes than for the 
others (Figure 4). This made binding constant calculation 
impossible, and suggests that the difference in binding strength 
of the two modes is less for these complexes than it is for the 
others. KLD was determined for 1, 3, 5 and 6 using binding 
curves from either one or two peaks in the induced spectrum; 
the average data is presented in Table 1 (see Table S1.2 for 
individual wavelength data). The points of the binding curve 
below 40 μM had to be removed in order to obtain a fit; this was 
due to the aforementioned DNA bending at these concentrations. 
The peak at ~320 nm for complexes 5 and 6 were not a result of 
DNA absorbance and so could be fitted with all points below 40 
μM. Each complex was found to bind to DNA with high potency. 
The intercalative binding strength of these PCs is attributed to 
stabilised - stacking as well as the longer range charge-
charge interactions of the platinum cations.[9] Complex 1 has the 
largest aromatic surface area and a binding constant of ~106 M-1. 
The other complexes had similar KLD values of 105 M-1. n 
(number of base-pairs per PC) values were typically around 2–3, 
indicating that each PC could intercalate between every second 
or third base pair in a sequence. Despite the lack of some 
binding data for complexes 2 and 4, LD has provided useful 
information regarding the binding activity of the PCs in this study. 
 
UV binding assays 
 
UV spectroscopy is a common method used to determine 
binding mode and affinity of metal complex-DNA interactions.[10] 
The addition of DNA to each of complexes 1-6 resulted in 
hypochromism, with a varying shift in wavelength between the 
PCs (Figure 5). The spectra of 3-6 were red-shifted with the 
effect being more subtle for 5 and 6, while the spectra of 1 and 2 
experienced a blue-shift upon the addition of CT-DNA. Typically 
these shifting patterns can provide information regarding the 
DNA binding mode;[10a] however, each of 1-6 absorb in the same 
region as DNA and so no definitive binding mode statements 
could be made from this data. Unlike the LD experiments, 
binding constant data was obtainable for all complexes in this 
instance, with no removal of binding curve points required 
(Figure 5). The possible secondary groove binding mode that 
limited the binding curves in LD had no effect here, and so the 
KUV values are likely reflective of an overall binding affinity rather 
than just an intercalation-related one. Due to the differences in 
the UV spectra of each complex, different wavelengths were 
chosen for each KUV determination. Where applicable, up to 
three wavelengths were chosen to facilitate a comparison 
between each value obtained; only minor differences were 
observed, and so the values in Table 1 are averages (see Table 
S2.2 for individual wavelength data). The KUV did not vary 
considerably with aromatic surface area, with most binding 
constants close to 105 M-1. The only exception is complex 4, 
which demonstrated higher DNA affinity with a KUV of ~106 M-1. 
This suggests that the 56Me2phen ligand, despite possessing a 
smaller aromatic surface than dpq or 23Me2dpq, is the optimum 
DNA-binding PL. Despite the lack of binding mode information 
relative to LD, UV spectroscopy has provided binding 
information for all concentration ranges without being restricted 
to one binding event. This in turn has allowed for binding data to 
be obtained for complexes 2 and 4 whereas LD could not do so. 







Figure 5. UV data for complex 4: spectra at various DNA concentrations (top), 
and fitted binding curve produced by the Mathematica script (bottom). The red 
dot indicates that the fit was successful.[11]  
Isothermal titration calorimetry 
 
ITC was employed here as it provides an overall picture of PC-
DNA binding interaction from a calorimetric perspective.[12] The 
titration of each of complexes 1–6 was exothermic in nature, 
with negative μcal sec-1 peaks present that represent DNA 
binding events, followed by smaller peaks from the heat of 
dilution once the binding sites were exhausted (Figure 6). Many 
titrations resulted in the appearance of two peaks rather than 
one, or at least evidence of two merged peaks to give the 
appearance of one. This suggests that binding may be biphasic 
in nature; the second peak may result from the ejection of 
solvent or sodium from the DNA sites, or from a DNA 
conformational adjustment post-binding, or both. The calculated 
thermodynamic parameters for each of 1–6 were similar. The 
binding of each complex with CT-DNA was an exothermic event, 
with ΔH values ranging from -1000 to -6000 cal mol-1 and ΔS 
values between 8 and 20 cal mol-1 deg-1 (Table 3). The positive 
ΔS is likely due to the solvation entropy that results from the 
ejection of solvent molecules from the grooves of DNA during 
PC-DNA binding.[13] The calculated ΔG values ranged between -
7500 and -8500 cal mol-1. Complexes 3 and 5 exhibited the 
lowest binding constants of ~2×105 M-1, while the values for 1, 2  
 
Figure 6. ITC trace and binding curve of the titration of complex 6 (650 μM) 
into CT-DNA (164 μM). Fits were obtained using a one-site binding model. 
and 6 were ~ 3×105 M-1. The only complex that appeared to bind 
with a distinctly higher affinity was complex 4 with a KITC of (5.7 ± 
0.5)×105 M-1. This again suggests that 56Me2phen is of an 
optimal size for DNA binding affinity. The number of PCs bound 
per base pair was between 0.25 and 0.3; converting that to n 
values reveals that approximately 3–4 binding sites are present 
per PC. 
 
Binding constant data comparison 
 
Overall, LD, UV and ITC have each provided valuable insight 
into the binding of complexes 1-6 to CT-DNA. LD has provided 
definitive evidence for an intercalative binding mode, however it 
could only provide binding constants for this interaction for four 
of the studied PCs. Evidence for a second electrostatic groove 
binding mode was also found in the LD spectra. UV 
spectroscopy provided binding data for all of 1–6 that resulted 
from the overall binding interaction; however no binding mode 
information could be obtained. ITC produced similar binding 
constants to the UV data, as well as additional thermodynamic 
information that could not be gained from the spectroscopic 
techniques. Each technique measures different aspects of PC-
DNA binding; LD quantified the intercalation event only, whereas 






      
Table 1. Summary of binding constant data obtained from LD (150 μM CT-DNA + 40-200 μM PC), UV (15μM PC + 7-200 μM CT-DNA) and ITC (titration of 600-
750 μM PC into 165 μM CT-DNA) experiments. Standard deviation values are included (1 sig. fig.). 
 LD Data UV Data ITC Data 
No. 10-5 KLD / M-1 n 10-5 KUV / M-1 n 10-5 K / M-1 n ΔH / kcal mol-1 TΔS / kcal mol-1 ΔG / kcal mol-1 
1 15.2 ± 0.4  2.41 ± 0.06 3.6 ± 0.2 3.13 ± 0.09 3.2 ± 0.3 3.98 ± 0.06 -4.4 ± 0.1 3.4 ± 0.1 -7.8 ± 0.3 
2[a] - - 4.7 ± 0.1 2.52 ± 0.01 2.8 ± 0.4 3.51 ± 0.08 -4.5 ± 0.1 3.2 ± 0.3 -7.7 ± 0.8 
3 2.8 ± 0.4 2.2 ± 0.2 2.9 ± 0.4 3.5 ± 0.3 2.0 ± 0.3 3.7 ± 0.1 -3.7 ± 0.1 3.9 ± 0.4 -7.5 ± 0.7 
4[a] - - 13 ± 1 2.32 ± 0.02 5.7 ± 0.5 3.00 ± 0.02 -5.6 ± 0.1 2.6 ± 0.2 -8.2 ± 0.6 
5[b] 2.1 ± 0.3 3.1 ± 0.3 0.79 ± 0.06 4.4 ± 0.2 2.2 ± 0.4 3.4 ± 0.1 -1.3 ± 0.1 6.2 ± 0.2 -7.6 ± 0.4 
6[b] 3.0 ± 0.5 2.1 ± 0.2 5.2 ± 0.6 2.87 ± 0.04 3.2 ± 0.4 3.57 ± 0.06 -3.6 ± 0.1 4.2 ± 0.1 -7.8 ± 0.2 
[a] LD values could not be determined due to a decrease in LD signal at high concentrations 
[b] LD values also reflect data in which binding data points below 40 μM could be fitted 
      
 
Figure 7. Comparison of the binding constants of complexes 1-6 with CT-DNA, 
as determined by ITC (red), UV (green) and LD (blue). Where applicable, K 
values over multiple wavelengths have been averaged for LD and UV data. 
UV and ITC provided data that was representative of the overall 
interaction from a spectroscopic and calorimetric perspective, 
respectively. Therefore it is not surprising that there were some 
differences in the calculated binding data across each technique 
(Table 1). More importantly, trends in DNA affinity for complexes 
1-6 are generally the same across all studies: 4 > 2 = 1 ≥ 6 = 3 ≥ 
5 (Figure 7). It is clear that these techniques are complementary 




Fluorescent intercalator displacement (FID) assays 
 
The ability to displace competing ligands from a target is a 
crucial factor in the efficacy of a drug. To study the ability of 
complexes 1-6 to competitively displace other binders from CT-
DNA, fluorescent intercalator displacement assays (FIDs) were 
utilised. Ethidium bromide (EtBr) was used here as it is 
fluorescent only when bound with DNA.[14] The peak of emission 
for DNA-bound EtBr is at ~601 nm; upon the addition of each PC, 
the emission intensity decreased, indicating that some EtBr had 
been displaced from the DNA strand (Figure 8). EtBr is 
postulated to occupy several binding sites of DNA with an  
 
Figure 8. Emission spectra of DNA (150 μM) bound with EtBr (75 μM) with 
increasing concentration of complex 3. Inset: the double-logarithm plot used to 
determine KF. 






overall KF of ~105 M.[15] Therefore, the determination of an 
accurate displacement binding constant is a difficult task as 
there are several possible sites occupied by EtBr that can be 
displaced by groove binders and intercalators alike. The binding 
curves obtained in this study did not reach a plateau, even at 
[DNA]: [PC] ratios as low as 0.15; this indicates that some 
ethidium molecules could not be displaced from particular 
binding sites. The curves could subsequently not be fitted using 
the same processing method as the LD and UV data, and so a 
simplified processing method of a previous study of ours was 
used (see Experimental for details).[6b] The results are 
summarised in Figure 9 and Table 2.  
 
Figure 9. Comparison of the KF and n determined for each PC, expressed on 
a logarithmic scale. Standard deviations (first significant figure) are included. 
Table 2. Fluorescence constants calculated for complexes 1–6, 
expressed with standard deviation (1 sig. fig.). 
No. 10-5 Kq / M–1 s–1 10-5 KF / M-1 n 
1 2.81 ± 0.03 0.46 ± 0.02 0.96 ± 0.01 
2 3.41 ± 0.02 1.59 ± 0.06 1.08 ± 0.01 
3 0.539 ± 0.009 0.019 ± 0.001 0.75 ± 0.01 
4 3.7 ± 0.1 6.6 ± 0.9 1.23 ± 0.01 
5 0.174 ± 0.004 0.0038 ± 0.0001 0.68 ± 0.01 
6 0.67 ± 0.01 0.030 ± 0.002 0.78 ± 0.01 
 
Each of the PCs studied was capable of displacing EtBr from the 
CT-DNA strand, with KF values between 102 and 107 M-1. The 
simplified processing method means that KF is only an indication 
of the ability of the complex to displace ethidium, and is not 
quantitatively representative of the binding affinity. Similarly, the 
calculated n values are representative of the amount of EtBr 
each complex can replace, rather than the number of DNA 
binding sites, and so it is logical that n values increased with 
increasing KF. Each PC demonstrated Kq values above ~2 × 1010 
M-1 s-1, indicating that EtBr displacement occurred prior to the 
measurement of emission.[16] The trends between complexes 1-
6 were still relatively consistent with the other data collected in 
this study; 4 and 5 demonstrated the highest and lowest affinity 
for CT-DNA, respectively. Greater differences were 
distinguishable between the rest of the complexes, suggesting 
that even the smallest differences in DNA affinity can result in 
large differences in competitive displacement ability that may be 
physiologically relevant. 
 
Synchrotron radiation circular dichroism 
 
SRCD has been used here to determine the effect of the binding 
of complexes 1-6 on the stability of CT-DNA. This was achieved 
through the determination of TM, the temperature inflexion point 
at which the CD signal is lost due to a loss of secondary 
structure.[17] The addition of each PC to CT-DNA resulted in 
dramatic changes in the SRCD spectrum, presumably due to 
conformational changes that occurred upon binding. The 
wavelength maxima and minima chosen for melting analysis 
differed for each of 1–6 as each complex influenced the CT-DNA 
spectrum in different ways. For each DNA-PC combination, CD 
signal decreased with increasing temperature (Figure 10), with 
melting occurring at different points for each PC. For each 
melting curve, the TM did not vary significantly between the 
wavelengths chosen. The binding of all complexes to DNA 
resulted in a higher TM than the average DNA value of 55 ± 1 oC 
(Figure 11). An increase in TM is expected for intercalative 
binders. It is important to note that the binding curves for  
 
 
Figure 10. SRCD spectra of CT-DNA (1 mM) bound with complex 5 (0.5 mM) 
at various temperatures. Inset: the melting curve used to generate the TM 
value (points past 62 oC have been omitted for clarity). 







Figure 11. Comparison of the SRCD ΔTM determined for CT-DNA bound with 
complexes 1–6. Standard deviations (error bars) are included. 
complexes 2 and 4 (Section S5) barely reached completion as 
the hardware could not raise the temperature above ~79 oC; 
however, ΔTM values were consistent between replicates. The 
trends in TM for each complex were almost the same as the 
trends of the fluorescence study; the order of DNA stabilisation 
was 2 ≅ 4 > 1 > 3 ≅ 6 > 5. Similarly to the FID assays, it 
appears that even minor differences in the DNA affinity of these 
PCs has led to large differences in their ability to stabilise helical 
DNA against melting. 
 
Mass Spectrometry Binding Studies 
 
Mass spectrometry is often used to probe ligand-biomolecule 
interactions at different stoichiometry.[18] The mass spectra of 
each of the double complementary strands 5ʹ-
GCGCATGCGCATGCGC-3ʹ (“GC Strand” or GCS) and 5ʹ-
GCATATGATATCATATGC-3ʹ (“AT Strand” or ATS) are 
characterised by several main peaks representing different 
charge states of the strand (Section S6). When binding to each 
strand individually, complexes 1-6 were found to bind to up to 
one in every two base-pairs. For example, for the solutions of 
9:1 PC to ATS strand ratio, the mass spectra for complex 2 
produced peaks corresponding to as high as [ATS+9PC], while 
those for 5 only produced peaks for up to [ATS+7PC]. Spectra 
and relative abundance information can be found in Section 
S6.2. To determine if there was any base-pair preference, a 
competitive assay was carried out in which each PC was added 
to a 1:1 solution of the GCS and ATS strands. All of complexes 
1–6 demonstrated the same behaviour in these experiments and 
so the spectra of complex 2 will be used as an example (Figure 
12). Immediate observation of the mass spectra of 1:1 GCS to 
ATS with one and three equivalents of complex 2 suggests that 
there is GC selectivity; in the 1:1:1 spectrum the peaks  
 
Figure 12. Mass spectra of a solution of complex 2, GCS (red symbols) and 
ATS (blue symbols) in the following ratios: 0:1:1 (bottom), 1:1:1 (middle) and 
3:1:1 (top) (1 equivalent is 42 μM). Legend: square = [DNA], triangle = 
[DNA+1PC], circle = [DNA+2PC], star = [DNA+3PC], diamond = [DNA+4PC]. 
corresponding to unbound GCS have dropped relative to the 
0:1:1 spectrum while the ATS peaks are still at large. Supporting 
this, the peaks at 1482 and 1741 m/z in this spectrum 
correspond to [GCS+1PC]. There is evidence for [ATS+1PC] at 
~1670 m/z, however this signal is also representative of 
unbound GCS and so the actual intensity would be quite low. 
The 3:1:1 spectrum further displays the GC selectivity of 
complex 2 as the ~1400 m/z peak representing unbound GCS at 
a charge of 7- has almost disappeared, while there is still some 
evidence of free ATS in the peaks at ~1660 and ~1800 m/z. 
Peaks corresponding to [ATS+1PC] (1666 and 1953 m/z) and 
[ATS+2PC] (1730 and 2050 m/z) are visible, however there are 
also peaks representative of [GCS+3PC] (1400 and 1870 m/z) 
and [GCS+4PC] (1950 m/z). GC selectivity is common for DNA 
intercalators,[19] and these experiments were conducted within 
DNA:PC ratios in which only intercalation is occurring (in 
accordance with the LD experimental data). Abundances were 
not determined here as there are too many overlapping peaks; 
however it is clear that the PCs in this study selectively bind to 
GC base-pairs over AT ones. 
 
In vitro cytotoxicity  
 
As a continuation of the cytotoxicity assays performed in 
previous work with complexes 1–6 and 1ʹ-6ʹ in the L1210 murine 
leukaemia, HT29 human colon carcinoma and U87 human 
glioblastoma cell lines,[5b] the activity of these complexes was 
assessed in a further ten cell lines: MCF-7 breast cancer, A2780 
ovarian cancer, H460 lung cancer, A431 skin cancer, Du145 
prostate cancer, BE2-C neuroblastoma, SJ-G2 human 
glioblastoma, MIA pancreas cancer, SMA murine glioblastoma 
and MCF10A breast (normal) (Table 3). These experiments 
were conducted to gain a greater understanding of the activity of 
1–6 and 1ʹ–6, to relate, if possible, the DNA affinity of 1–6 with 
their in vitro activity, and to determine particularly sensitive cell 
lines to target in further studies. For all cell lines studied, the 
complexes demonstrated potent, often sub-micromolar activity,







Figure 13. Comparison of the cytotoxicity of complexes 1–6 and 1ʹ–6ʹ in the SJ-G2 human glioblastoma (blue), HT29 colon carcinoma (red) and Du145 prostate 
cancer (green) cell lines, expressed as nanomolar IC50 values with standard error. Carboplatin and BPYRR (5') values have been omitted for clarity. 
with complexes 3-6 demonstrating very high cytotoxicity in the 
Du145 prostate cancer (some values previously published[20]), 
SJ-G2 glioblastoma, and the previously published HT29 colon 
carcinoma[5b] lines (Figure 13). These cancer types are therefore 
good targets for further therapeutic studies. The lowest point of 
activity was in the BE2-C neuroblastoma line, with only 
complexes 3 and 4 reaching sub-micromolar IC50 concentrations. 
Also of note is the higher cytotoxicity of all PCs in the “normal” 
MCF10A breast cell line relative to the MCF-7 breast cancer line. 
This emphasises the importance of targeted delivery of these 
complexes to cancerous cells. Across the majority of cell lines, 
the same structure-activity trends are observed as previous 
studies: for PLs, 56Me2phen > phen ≥ 44Me2bpy > dpq > bpy ≅ 
23Me2dpq, and for ALs, SS-dach > RR-dach. The fact that these 
trends were generally the same across all cell lines suggests 
that the in vitro mechanism of action of these PCs is largely 
independent of the cancer type, with minor differences between 
the mechanisms of individual complexes. A correlation between 
DNA affinity and cytotoxicity was observed for complexes 3–6; 4 
and 5 were the most and least effective in both areas, 
respectively, while 3 and 6 were approximately equal in both 
DNA affinity and cytotoxicity. Interestingly, complexes 1 and 2 
exhibited mid-low biological activity despite their relatively high 
DNA affinity. Additionally there were large differences in activity 
between R,R and S,S isomers, despite their similar DNA binding 
affinity as determined in our previous DNA study.[6b] This 
reinforces the notion that the apoptotic mechanisms of these 
complexes involve much more than DNA binding alone.[4, 21] 
Further studies of the in vitro interactions of these complexes 
are warranted. 
Conclusions 
The DNA binding of six anticancer PCs DPQSS, 23MEDSS, 
PHENSS, 56MESS, BPYSS and 44MEBSS has been studied in 
depth through the use of several biophysical techniques. Overall, 
each technique contributed unique information regarding binding 
behaviour; LD, UV and ITC provided PC-DNA binding constant 
values, as well as binding mode and thermodynamic parameters. 
From this data it is clear that complexes 1–6 are capable of 
binding to DNA with an affinity of ~105–106 M-1, with intercalation 
as the primary mode and other potential modes at higher PC 
concentrations. FID and SRCD experiments provided some 
insight into the effect of DNA affinity on the ability of the PCs to 
displace competing binders and to stabilise the DNA strand, 
respectively. Overall, 56MESS (4) and BPYSS (5) were found to 
be the most and least potent DNA binders, respectively. Finally, 
mass spectrometry studies revealed that each PC preferentially 
binds to GC base-pairs over AT ones. The unique information 
gleaned from each of these biophysical methods, and the minor 
differences in trends observed from each, clearly reveal that in 
order for one to have a complete understanding of the binding of 
small molecules to DNA, multiple techniques of analysis should 
be utilised. Complexes 1–6 and 1ʹ–6ʹ demonstrated high in vitro






            
Table 3. Summary of the in vitro cytotoxicity of complexes 1–6 and 1ʹ–6ʹ in several cell lines, expressed as an IC50 value with standard error (1 sig. fig.). IC50 is the concentration at which cell growth is inhibited by 50% over 72 h. 
  IC50 (μM) 
Complex L1210[a] HT29[a] U87[a] MCF-7 A2780 H460 A431 Du145 BE2-C SJ-G2 MIA SMA MCF10A 
1 DPQSS 0.19 ± 0.01 0.59 ± 0.08 3.70 ± 0.24 1.8 ± 0.2 2.0 ± 0.1 1.9 ± 0.2 3.2 ± 0.2 0.44 ± 0.06 2.9 ± 0.2 2.5 ± 0.3 0.62 ± 0.03 1.3 ± 0.6 1.6 ± 0.2 
1ʹ DPQRR 0.8 ± 0.2 1.3 ± 0.2 12 ± 2.8 7.8 ± 0.8 6.5 ± 0.0 3.9 ± 0.2 7 ± 2 2.7 ± 0.2 24 ± 3 12 ± 3 2.3 ± 0.3 7 ± 2 6 ± 1 
2 23MEDSS 1.3 ± 0.4 1.8 ± 0.3 8.2 ± 1.6 4.2 ± 0.4 3.7 ± 0.4 2.8 ± 0.1 13 ± 2 2.2 ± 0.1 34 ± 6 13 ± 1 0.7 ± 0.2 5.2 ± 0.4 4.3 ± 0.7 
2ʹ 23MEDRR 6 ± 2 1.6 ± 0.4 16 ± 3.2 4.4 ± 0.7 2.0 ± 0.1 8.0 ± 0.5 7 ± 2 3 ± 1 1.80 ± 0.06 6 ± 2 1.2 ± 0.3 2.1 ± 0.6 4 ± 1 
3 PHENSS[b] 0.10 ± 0.01 0.13 ± 0.04 1.5 ± 0.4 0.5 ± 0.2 0.27 ± 0.03 0.5 ± 0.2 0.9 ± 0.3 0.08 ± 0.05 0.40 ± 0.05 0.45 ± 0.06 0.8 ± 0.7 0.24 ± 0.04 0.16 ± 0.07 
3ʹ PHENRR 1.5 ± 0.1 0.56 ± 0.08 8.9 ± 2.5 3.2 ± 0.2 2.70 ± 0.07 7.2 ± 0.9 2.0 ± 0.6 0.79 ± 0.08 3.8 ± 0.4 3.3 ± 0.3 2.7 ± 0.2 3.2 ± 0.3 2.4 ± 0.3 
4 56MESS[b] 0.009 ± 
0.002 












4ʹ 56MERR[b] 0.46 ± 0.01 0.19 ± 0.00 2.2 ± 0.058 0.8 ± 0.1 1.1 ± 0.1 1.8 ± 0.2 0.93 ± 0.03 0.41 ± 0.04 2.3 ± 0.2 2.2 ± 0.2 0.45 ± 0.006 1.6 ± 0.5 0.39 ± 0.01 
5 BPYSS 0.6 ± 0.2 1.1 ± 0.2 4.0 ± 0.3 2.6 ± 0.2 2.6 ± 0.2 5 ± 2 3.1 ± 0.2 1.3 ± 0.4 3 ± 1 1.8 ± 0.3 2.5 ± 0.1 3.1 ± 0.8 1.6 ± 0.3 
5ʹ BPYRR[c] 5.5 ± 0.1 - - - - - - - - - - - - 
6 44MEBSS 0.36 ± 0.02 0.13 ± 0.03 0.500 ± 0.009 3.5 ± 0.7 0.9 ± 0.1 1.1 ± 0.3 0.5 ± 0.1 0.12 ± 0.03 1.0 ± 0.5 0.55 ± 0.04 3 ± 1 0.29 ± 0.03 0.27 ± 0.02 
6ʹ 44MEBRR 1.8 ± 0.0 0.66 ± 0.07 3.9 ± 0.4 2.70 ± 0.07 5 ± 1 5.6 ± 0.5 1.4 ± 0.4 1.5 ± 0.3 5.2 ± 0.4 3.0 ± 0.2 3.4 ± 0.2 2.7 ± 0.2 2.0 ± 0.3 
 Cisplatin 0.35 – 1[d] 11 ± 2 3.8 ± 1.1 6.5 ± 0.8 1.0 ± 0.1 0.9 ± 0.2 2.4 ± 0.3 1.2 ± 0.1 1.9 ± 0.2 0.4 ± 0.1 8 ± 1 1.2 ± 0.1 nd 
 Oxaliplatin nd 0.9 ± 0.2 1.8 ± 0.2 0.5 ± 0.1 0.16 ± 0.0 1.6 ± 0.1 4.1 ± 0.5 2.9 ± 0.4 0.9 ± 0.2 3 ± 1 0.9 ± 0.2 1.4 ± 0.1 nd 
 Carboplatin nd >50 >50 >50 9 ± 3 14 ± 1 24 ± 2 15 ± 1 19 ± 1 5.7 ± 0.2 >50 14.3 ± 0.7 nd 
[a] – quoted from ref.[5b] and those within. 
[b] – values for these complexes were also previously reported in ref.[20] 
[c] – pre-screening determined this complex was not active most Calvary Mater cell lines 
[d] – values also retrieved from refs.[6b, 22] 






activity across a large range of human cancer cell lines with 
particularly high efficacy in Du145 prostate cancer and SJ-G2 
glioblastoma cells. PCs of dpq and 23Me2dpq, despite 
demonstrating relatively high DNA affinity, were among the least 
active biologically. For complexes of bpy, 44Me2bpy, phen and 
56Me2phen, DNA affinity does appear to correlate with 
cytotoxicity, suggesting that DNA binding plays a role in the 
apoptotic activity of these complexes. However, the large 
difference in activity between enantiomers suggests that further 
studies of other, non-DNA interactions are needed to determine 
the overall mechanism of action. 
Experimental Section 
Materials and Preparation 
All reagents were used as received and all solvents used were of 
analytical grade or higher. Complexes 1–6 and 1ʹ–6ʹ were prepared as 
per previous publications.[5b, 6b, 22] Dipotassium hydrogen orthophosphate, 
potassium dihydrogen orthophosphate, ammonium acetate, sodium 
fluoride, sodium chloride, D-10-camphorsulfonic acid, calf-thymus DNA 
and ethidium bromide (EtBr) were obtained from Sigma-Aldrich 
chemicals. Pora-Pak™ Rxn CX cartridges (20cc, 2g) were obtained from 
Waters. The HPLC-purified DNA oligonucleotides 5ʹ-
GCGCATGCGCATGCGC-3ʹ (“GC Strand” or GCS) and 5ʹ-
GCATATGATATCATATGC-3ʹ (“AT Strand or ATS”) were obtained from 
Integrated DNA Technologies (IDT). Further purification and ion 
exchange of each strand was achieved by dissolution in 150 mM 
ammonium acetate and elution through a Pora-Pak™ Rxn CX cartridge 
(20cc, 2g) followed by lyophilisation. Annealing was achieved by heating 
solutions of each oligo in 150 mM ammonium acetate to 95 oC in a water 
bath for 3 min before leaving the water bath to cool overnight. Oligo 
concentrations were determined through UV absorbance, using the IDT-
provided extinction coefficients of 254000 and 283000 M-1cm-1 per double 
strand at 260 nm for GCS and ATS, respectively. CT-DNA concentration 
was confirmed using the 260 nm extinction coefficient of 13200 M-1cm-1 
per base pair.[23] Ethidium bromide concentration was determined using 
the extinction coefficient of ε476 = 5680 M-1cm-1,[24] and PC concentrations 
were determined using their respective extinction coefficients (Table 4).[5b, 
6b, 25] 
 
Table 4. Wavelength maxima and extinction coefficients of 
complexes 1–6. 
No. PL λmax / nm ε / M-1 cm-1 
1 Dpq 258 50000 
2 23Me2dpq 261 45000 
3 Phen 226 35000 
4 56Me2phen 230 37000 
5 Bpy 245 22000 
6 44Me2bpy 243 24500 
 
Linear dichroism 
LD spectra were obtained using a Jasco 810 spectropolarimeter using a 
quartz capillary LD Couette flow cell built by Crystal Precision Optics. 
Experiments at temperatures close to physiological resulted in DNA 
shearing, and so experiments were performed at 20 oC rather than 37 oC.   
The instrument was allowed to equilibrate for 30 min prior to use, and 
nitrogen gas flow was kept at ~10 L min-1. A series of ~17 solutions 
consisting of CT-DNA (150 μM), K2HPO4/KH2PO4 (10 mM, pH 7.3), NaCl 
(10 mM) and various amounts of each PC were prepared according to 
Table S1.1. NaCl concentration was relatively low due to the strong 
absorption of chloride salts at low wavelengths.[26] For each solution, 
spectra were obtained over the range of 200–350 nm using a scan rate 
of 200 nm min-1, data pitch of 1 nm, response time of 1 s and rotation 
speed of 3000 rpm. Two accumulations were collected and a baseline 
non-rotating spectrum was subtracted from each data set. The change of 
the DNA signal in proportion to the PC concentration was used to 
elucidate PC-DNA binding information, and to determine the binding 
constant for LD (KLD). To determine the binding constants, the induced 
response of the LD signal was plotted against PC concentration, and 
fitted to the following equation using the published Wolfram Mathematica 




where LT is the total PC concentration, BT is the total number of DNA 
bases, KLD is the binding constant and n is the number of base-pairs per 
PC. RB is the response of the instrument as a result of the binding of PC 
to DNA (whose concentration is denoted LB) and ε is an experimental 
measurement that relates to LB via: 
 
 
KLD was calculated for each wavelength peak in the induced spectrum of 
complexes 1, 3, 5 and 6. For all signals below 300 nm, the points of the 
binding curve corresponding to PC concentrations below 40 μM had to 
be removed in order to fit the data. The peak at ~320 nm for complexes 5 
and 6 were not a result of DNA absorbance and so they could be fitted 
with all points below 40 μM. Experiments were performed in triplicate for 
each PC. 
UV spectroscopy 
Absorbance spectra were obtained using a Jasco V-660 UV/vis 
spectrometer operating at 37 oC. The wavelength range chosen was 200-
450 nm, and the scan rate was 400 nm min-1, data interval was 1 nm and 
averaging time was 0.1 s. The spectrum of each PC (~14 μM) in 
K2HPO4/KH2PO4 (10 mM, pH 7.3) and NaCl (50 mM) buffer was initially 
obtained, followed by the titration of CT-DNA (1–2 mM) according to 
Table S2.1. The same amount of DNA and buffer was added to the 
reference cell to account for the absorbance of DNA. After each titration, 
the solutions were gently mixed and allowed to incubate for 2 min before 
measurement. The attenuation of signal at various wavelengths for each 
PC was used to determine the binding constant (KUV) for each complex. 
The binding of each PC to CT-DNA was studied quantitatively using the 
same Wolfram Mathematica script as the LD experiments, to determine 
the binding constant (KUV) and number of binding sites. It is important to 
note that many UV binding studies report much smaller changes in signal, 






and so the script may not always be able to find a fit. Experiments were 
performed in triplicate for each PC. 
Isothermal titration calorimetry assays 
ITC traces were obtained using a MicroCal iTC 200 calorimeter operating 
at 37 oC. Each PC (600–750 μM) was titrated into a solution of CT-DNA 
(165 μM) in K2HPO4/KH2PO4 (10 mM, pH 7.3) and NaCl (50 mM) buffer. 
Each PC was also titrated into buffer without DNA for use as a baseline.  
The titration program consisted of one 0.4 μL addition followed by 18 
titrations of 2 μL, with a spacing of 180 s, reference power of 6 μcal s-1 
and stirring speed of 750 rpm. Data was analysed using Origin 7.0 
(MicroCal version) using 200 iterations of a one-site binding model using 




Fluorescent intercalator displacement assays 
Emission spectra for the FIDs were collected using a Jasco FP-2500 
fluorimeter operating at 37 oC. The wavelength range chosen was 550–
750 nm with an excitation wavelength of 480 nm, scan rate of 600 nm 
min-1, data interval of 1 nm and averaging time of 0.1 s. The emission 
and excitation slits were each set to 5 nm. A solution of EtBr (75 μM) and 
CT-DNA (150 μM) in K2HPO4/KH2PO4 (10 mM, pH 7.3) and NaCl (50 
mM) buffer was initially measured, followed by the titration of PC (various 
concentrations) according to Tables S4.1 and S4.2.  After each titration 
the solution was gently mixed and incubated for 3 min before 
measurement. The attenuation of signal at 601 nm from each successive 
titration was used to calculate the binding constant for fluorescence (KF). 




where F0 is the fluorescence of the binding site in the absence of 
quencher, F is the fluorescence of the site containing the PC, Kq is the 
bimolecular quenching constant, τ0 is the lifetime of the chromophore in 
the absence of the quencher (~22 × 10-9 s for ethidium-bound DNA),[29] 
and KSV is the Stern-Volmer quenching constant. A plot of F0/F against 
[PC] using experimental values allows for the determination of Kq and KSV 
from the slope. To determine KF, the double-logarithm expression derived 
in our previous work was used to determine a binding constant for the 
PC-DNA interaction:[6b]  
 
 
where n is the number of ethidium compounds displaced per PC. It is 
important to note that this expression is a simplification of the true 
binding interaction as the effect of EtBr on the binding equilibrium is 
ignored;[30] however, the results obtained are still comparable between 
complexes of the same study.[6b] A plot of log10[(F0 – F)/F)] against 
log10[PC] is used to determine KF and n from the intercept and slope, 
respectively. Experiments were performed in triplicate for each PC. 
Synchrotron radiation circular dichroism 
Experiments were performed at the AU-CD beamline on ASTRID2[31] at 
ISA, Aarhus University. ASTRID2 operates in top-up mode with a current 
of 120 mA. The AU-CD beam line operates in the wavelength range of 
125 to 450 nm, with a bandwidth of 0.6 nm. The beam size on the 
sample is 2 (vert.) × 6 (horz.) mm, with, a sample to detector distance of 
25 mm. All SRCD experiments were performed using a suprasil quartz 
cuvette with a 0.01 cm path length. Temperature control was achieved 
through the use of a Eurotherm temperature regulator. Calibration of the 
spectropolarimeter was assessed through daily measurement of the CD 
spectrum of D-10-camphorsulfonic acid. Each melting solution consisted 
of a PC (0.5 mM) and CT-DNA (1 mM) in K2HPO4/KH2PO4 (10 mM, pH 
7.3) and NaF (50 mM) buffer. NaF was used due to the strong absorption 
of chloride salts at low wavelengths.[26] Solutions of CT-DNA with no PC 
present were also measured. Temperature scans were performed as 
follows: the cell temperature began at 25 oC, was raised to 45 oC in 10 oC 
increments and then raised from 45–90 oC in 5 oC increments. The 
heating rate was 1 oC.min-1. For each temperature increment, the cell 
was allowed to equibrilate for 5 min before a spectrum was recorded; 
these were collected from 350–170 nm with a 1 nm increment and three 
accumulations. Prior to each melting experiment, a baseline spectrum of 
the PC in phosphate buffer was obtained to partially eliminate the effects 
of PC chirality from the SRCD spectra. Experiments were performed in 
duplicate for each PC. For each wavelength, SRCD intensity was plotted 
against temperature, and a Boltzmann curve was fitted to the plot using 
Origin Pro 8.5 (Origin Labs) to determine the TM. The CT-DNA 
concentration used here was much higher than that for other biophysical 
assays due to the lower path length of the cell used. To prevent the 
chirality of the PCs from affecting the CD spectrum of DNA, the PCs 
were included in the baseline solutions and the DNA:PC ratio was 
consistently kept at 2:1 and no higher. 
Electrospray Ionisation Mass Spectrometry 
DNA-PC solutions were analysed via negative-mode ESIMS using a 
Waters XEVO QToF ESI mass spectrometer with a Z-spray ionisation 
source. Mass spectra were obtained with a MCP potential of 2400 V, a 
cone voltage of 25 V and a capillary tip potential of 2.4 kV. The 
desolvation gas flow was 300 L/h at a desolvation temperature of 150 oC 
with the source temperature at 70 oC. The collision energy was set to off. 
Spectra were obtained over a mass/charge (m/z) range of 50–4000. A 
Hamilton 250 µL model 1725RN gastight syringe was loaded with 25 µL 
of solution and infused into the mass spectrometer source using a KD 
Scientific model 100 syringe pump set to 5 µL min-1, achieving 5 minutes 
of data acquisition. Between each run the syringe was cleaned 
thoroughly and the mass spectrometer was flushed with MilliQ-purified 
water. 
In-vitro cytotoxicity 
Cytotoxicity assays were performed at the Calvary Mater Newcastle 
Hospital, Waratah, NSW, Australia. The cell lines tested were MCF-7 
breast cancer, A2780 ovarian cancer, H460 lung cancer, A431 skin 
cancer, Du145 prostate cancer, BE2-C neuroblastoma, SJ-G2 
glioblastoma, MIA pancreas cancer, SMA murine glioblastoma and the 
non-tumour derived MCF10A breast cell lines. All test agents were 
prepared as 30 mM stock solutions in DMSO and stored at -20 ºC. Cell 
lines were cultured in a humidified atmosphere 5% CO2 at 37 ºC and 
maintained in Dulbecco’s modified Eagle’s medium (Trace Biosciences, 






Australia) supplemented with 10% foetal bovine serum, 10 mM sodium 
bicarbonate penicillin (100 IU mL-1), streptomycin (100 µg mL-1), and 
glutamine (4 mM). Cytotoxicity was determined by plating cells in 
duplicate in 100 mL medium at a density of 2,500–4,000 cells per well in 
96 well plates.  On day 0, (24 h after plating) when the cells were in 
logarithmic growth, 100 L medium with or without the test agent was 
added to each well.  After 72 h drug exposure growth inhibitory effects 
were evaluated using the MTT (3-[4,5-dimethyltiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide) assay and absorbance read at 540 nm.  An eight 
point dose response curve was produced from which the IC50 value was 
calculated, representing the drug concentration at which cell growth was 
inhibited by 50% based on the difference between the optical density 
values on day 0 and those at the end of drug exposure.[32] 
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DNA binding behaviour of six 
polyaromatic platinum anticancer 
complexes has been studied using six 
biophysical methods (linear dichroism 
pictured), resulting in a comparison of 
the merits of each technique and the 
establishment of trends in DNA affinity 
in relation to complex structure. In 
vitro cytotoxicity in a panel of human 
cells was determined, revealing sub-
micromolar activity in Du145 and SJ-
G2 cells. Correlations between activity 
and DNA affinity were determined.  
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